Somaxon Sees “Clear Path” For Silenor Sleep Aid Switch
This article was originally published in The Tan Sheet
Executive Summary
Somaxon Pharmaceuticals expects to make Silenor sleep aid available OTC in five to seven years.
You may also be interested in...
Silenor Deal Gives P&G Easy Access To Rx Market, Possible OTC Sales
Procter & Gamble's license to market the insomnia drug Silenor lets the firm re-enter the Rx drug market without development costs and opens the door to a potential OTC switch
Somaxon's Silenor Gains An FDA Approval, But Can The Pharma Afford A Launch?
Somaxon hopes to launch its insomnia drug in the second half of 2010, but is still searching for a U.S. commercial partner.
Somaxon Sleep Aid Silenor Not Effective, FDA Says
In its second "complete response" letter for the chronic insomnia drug, FDA says Silenor fails to meet approval standards.